Royalty Pharma.

Novartis Phase 3 Pelacarsen Trial Misses Cardiovascular Endpoint

Novartis reported that the Phase III Lp(a)HORIZON trial did not meet its primary endpoint, showing that lowering Lp(a) with pelacarsen reduced levels but did not significantly reduce cardiovascular events in approximately 8,000 patients on guideline-directed therapy; the company said full data will be presented at a future medical congress. Meanwhile, Royalty Pharma outlined its financial stance on the pelacarsen investment, noting the trial’s failure won’t derail its recovery of invested funds and that royalties on Spinraza remain a key part of its portfolio as it pursues its 2030 receipts target, with Ionis royalties potentially reverting after a defined cap. The developments reflect a broader scientific and market reevaluation of Lp(a)-targeted therapies and their commercial prospects.